ZVRA
High convictionZevra Therapeutics, Inc.
Healthcare · NASDAQ
$799.2M mkt cap
Brief updated Jun 28, 2026
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions
ZVRA is a high-conviction name in Healthcare
ZVRA sits at the intersection of key themes currently active in the market. The scoring engine rates it high based on how well the active market forces line up with its business, plus available fundamental data. Financial metrics and analyst consensus provide additional context.
Why now
The market forces active right now are aligned with the company's core business exposure. The timing reflects the intersection of theme strength and available catalyst data.
Key risks
Data availability limits full scoring across all dimensions. Market forces can reverse rapidly; theme exposure does not guarantee the price follows. Fundamental valuation data may not reflect the most recent quarterly results.
What to watch
Monitor conviction score changes, especially the macro and analyst dimensions. Earnings guidance updates and analyst consensus shifts are the primary near-term catalysts.
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Amid US Attacks on Iran
The US has launched attacks on Iran, leading to increased geopolitical tensions and a rise in risk-off sentiment, with exchange-traded funds and equity futures higher pre-bell on Thursday as investors seek safe-haven assets.
Jun 15, 2026
Circle Your Calendars for July 29. JPMorgan Executive Says Fed Chair Kevin Warsh Could Raise Rates in As Little as Six Weeks.
JPMorgan executive suggests Fed Chair Kevin Warsh may raise interest rates as early as six weeks from July 29, indicating a potential shift in monetary policy. This could impact market expectations and asset prices.
Jun 22, 2026
Gold Extends Losses as Fed Rate-Hike Outlook Supports Dollar
The Federal Reserve's outlook on interest rate hikes has strengthened, supporting the US dollar and leading to extended losses in gold prices. This development may impact investor risk appetite and currency markets.
Jun 22, 2026
Chart of the Day 6-19-26- In Warsh's Wake, Hike Odds Spike
The odds of a interest rate hike have increased following comments from a key central bank official, indicating a potential shift in monetary policy. This change in guidance could impact market expectations and asset prices.
Jun 22, 2026
Earnings surprises
+200.0%
2026-05
+2201.6%
2026-03
+50.0%
2025-11
-44.8%
2025-08
+71.4%
2025-05
TSMC stock drops 4.1% amid a $2 trillion AI rout, indicating a potential shift in investor sentiment towards AI-related stocks and the broader tech sector. This event may have implications for the tech industry and the global economy.
The US equity indexes are sliding ahead of Fed Governor Warsh's press briefing and big-tech results, as President Trump vows to hit Iran hard, escalating geopolitical tensions. This escalation could lead to increased market volatility and risk aversion.
The equities market is experiencing intraday losses ahead of the highly anticipated Federal Reserve decision, which could significantly impact market direction and investor sentiment. The decision, coupled with major tech earnings reports, is poised to influence the overall economic outlook.
Escalating tensions between the U.S. and Iran are weighing on broader market sentiment, causing investors to reduce exposure to risk assets, including crypto-linked companies. This geopolitical uncertainty is leading to a decline in Bitcoin prices and affecting market sentiment.
The US-Iran war fear has reemerged, causing the S&P 500, Nasdaq, and Dow to end lower, as investors become increasingly risk-averse due to the potential for conflict escalation.
Generated Sun, 28 Jun 2026 07:00:10 GMT by Decifer intelligence engine. For informational purposes only — not investment advice. Decifer Intelligence Hub.